Researchers compare the therapeutic efficacy of risakizumab and ustekinumab for the treatment of moderate-to-severe Crohn’s disease.
By Dr. Sanchari Sinha Dutta, Ph.D.Reviewed by Benedette Cuffari, M.Sc.Aug 23 2024 In a recent study published in The New England Journal of Medicine , researchers discuss the results of a randomized clinical trial comparing the therapeutic efficacy of risakizumab and ustekinumab for the treatment of moderate-to-severe Crohn’s disease.
Interleukin-23 is a proinflammatory cytokine comprising a p40 subunit shared with IL-12 and a unique p19 subunit that plays a key role in skin, joint, and gastrointestinal inflammation. Ustekinumab and risankizumab are humanized monoclonal antibodies that selectively bind to p40 and p19 subunits, respectively. Previous clinical trials have indicated the therapeutic efficacy of these antibodies against plaque psoriasis, psoriatic arthritis, and Crohn’s disease.
Patients were randomly assigned to receive either the standard dose of risankizumab or ustekinumab for 48 weeks. Two primary treatment outcomes were tested sequentially, of which included clinical remission at week 24 and endoscopic remission at week 48. The superior efficacy of risankizumab At week 24, clinical remission occurred in 58% of risankizumab-treated patients and 39% of ustekinumab-treated patients. The analysis of primary treatment outcomes at week 48 revealed that endoscopic remission of the disease occurred in 31% and 16% of risankizumab- and ustekinumab-treated patients, respectively, thus indicating the superior efficacy of risankizumab as compared to ustekinumab.
Safety assessment The percentages of patients who experienced any adverse event or a severe adverse event, including serious infections or hepatic events, were comparable between the two treatment groups. However, the risk of serious adverse events related to worsening of underlying Crohn’s disease was lower in the risankizumab treatment group as compared to ustekinumab recipients.
Antibodies Chronic Clinical Trial Efficacy Glucocorticoid Inflammation Inflammatory Bowel Disease Interleukin Medicine Necrosis Tumor Tumor Necrosis Factor
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
BYU researchers develop first national glycemic index database for U.S. dietsKaren Della Corte, BYU nutrition and dietetics professor, recently authored a new study, published in The American Journal of Clinical Nutrition, that developed a national glycemic index (GI) and glycemic load (GL) database to offer insights into the evolving quality of carbohydrates consumed in the United States, something that hadn't been done...
Read more »
Researchers develop highly reactive RNA building blocks for enhanced chip productionAn international research team led by the University of Vienna has succeeded in developing a new version of RNA building blocks with higher chemical reactivity and photosensitivity. This can significantly reduce the production time of RNA chips used in biotechnological and medical research.
Read more »
Cracking the carb code: Researchers create new glycemic index database to improve dietary awarenessKaren Della Corte, BYU nutrition and dietetics professor, recently authored a new study, published in The American Journal of Clinical Nutrition, that developed a national glycemic index (GI) and glycemic load (GL) database to offer insights into the evolving quality of carbohydrates consumed in the United States, something that hadn't been done...
Read more »
World first discoveries allow researchers to accurately diagnose prenatal exposure syndromes and birth disordersResearchers at London Health Sciences Centre (LHSC) and Lawson Health Research Institute are using advanced technology and artificial intelligence (AI) to diagnose rare diseases and prenatal exposure-related birth abnormalities in two studies published today, one study in American Journal of Human Genetics and the other in Genetics in Medicine.
Read more »
Researchers use AI-powered method to identify genetic epilepsies earlier than current genetic diagnosisDiagnosing the genetic cause of a disease can aid in finding therapies and directing treatment, but often these diagnoses occur long after the disease has impacted a patient's life.
Read more »
Researchers use waves to quantify blood vessels' architectureResearchers from the King's College London School of Biomedical Engineering & Imaging Sciences, along with partners at the University of Michigan, The Institut national de la santé et de la recherche médicale (France), Norway, and Germany are using shear waves to map blood vessel structures.
Read more »